IPO - Profile

Summary

We are a clinical-stage biopharmaceutical company currently focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases. We utilize our proprietary oligonucleotide and small molecule platforms to develop pharmacologically optimized drug candidates for use in combination regimens designed to achieve improved treatment outcomes.

Our lead effort is to develop a functional cure for Chronic Hepatitis B (“CHB”), which often results in other life-threatening conditions such as cirrhosis, end-stage liver disease (“ESLD”) and the most common form of liver cancer, hepatocellular carcinoma (“HCC”). The most widely used More

Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$15.00 10,000,000 Positive High 27.61%

Offering Team

  • Legal counsel
  • Latham & Watkins LLP
  • Auditors
  • Ernst & Young LLP

Deal Highlights

Deal Tracker

IPO Dates

Filing 09 Oct, 2020

Offer 16 Oct, 2020

Look Ahead

Lock Up Expiry Apr 16, 2021

IPO Terms

Offer Price $15.00
Offer Size 10M

Market Sentiments

Stock Price